IGF-1 LR3

The speaker includes significant cardiovascular disease as a condition requiring caution prior to IGF-1 LR3 use. This is presented alongside inflammatory conditions and uncontrolled diabetes as part of a comorbidity-based risk stratification approach. No specific cardiovascular parameters or dosage considerations are discussed. The recommendation reflects the speaker's clinical practice pattern.

The speaker flags uncontrolled diabetes as a condition warranting caution before using IGF-1 LR3. This is consistent with known IGF-1 axis interactions with insulin signaling and glucose metabolism. No specific glycemic thresholds or dosage modifications are provided. The caution is presented as part of a broader patient screening framework.

The speaker recommends exercising caution when considering IGF-1 LR3 use in patients who have active inflammatory conditions. This is presented as a clinical judgment call rather than an absolute contraindication. No specific inflammatory conditions are named, and no dosage adjustments are suggested. The warning is grouped alongside other comorbidity-based cautions.

The speaker issues a firm contraindication, stating that individuals with a personal or family history of hormone-sensitive cancers, or those with active neoplastic disease, should not use IGF-1 LR3 under any circumstances. This is framed as a hard stop with emphatic language ('full stop'). No dosage threshold is discussed as mitigating this risk. This represents the speaker's strongest safety warning in the transcript.

The speaker states there is no conclusive evidence that IGF-1 LR3 causes cancer, offering a measured qualification to the cancer concern. This is presented as a current state-of-evidence assessment rather than a citation of a specific trial or study. No dosage information is provided. The statement serves to contextualize risk without dismissing it.

The speaker explains that the same cellular pathways IGF-1 LR3 activates for muscle repair and cellular proliferation are the identical pathways that cancer cells exploit for growth. This mechanistic overlap is presented as the core biological concern with IGF-1 LR3 use. No specific dosage is mentioned in this context. The claim is framed as a mechanistic rationale rather than citing a specific study.

IGF-1 LR3 is presented as a modified, engineered analog of native IGF-1 specifically designed to circumvent the IGFBP sequestration problem. By reducing binding affinity to IGFBPs, IGF-1 LR3 is implied to have greater free bioavailability compared to regular IGF-1. No specific dosages, study citations, or clinical trial data are provided in this transcript excerpt.